appendix
play

Appendix Potential target patient populations 2018 Oncology - PowerPoint PPT Presentation

Jul 14, 2023 •41 likes •531 views

Appendix Potential target patient populations 2018 Oncology Hemophilia A Ophthalmology Infectious diseasese Neuroscience Immunology 2 Herceptin + Perjeta, Tecentriq: HER2+ early Breast Cancer (eBC) 2018 estimates for number of patients 3

  1. Appendix Potential target patient populations 2018

  2. Oncology Hemophilia A Ophthalmology Infectious diseasese Neuroscience Immunology 2

  3. Herceptin + Perjeta, Tecentriq: HER2+ early Breast Cancer (eBC) 2018 estimates for number of patients 3 Source: Roche/Genentech

  4. Perjeta, Herceptin, Kadcyla, Tecentriq: HER2+ metastatic Breast Cancer (mBC) The target US and EU 5 population for 1L HER2+ mBC is ~19,300 patients (7,800 de novo and 11,400 adjuvant relapse) • The target US and EU 5 population for 2L-4L HER2+ mBC is ~34,900 patients (~19,700 US/~15,200 Top 5 EU) • 2018 estimates for number of patients 4 Source: Roche/Genentech; Kadcyla in collaboration with ImmunoGen

  5. Ipatasertib: HER2-/HR+ 1L and recurrent mBC 2018 estimates for number of patients 5 Source: Roche/Genentech; *2/3L includes HR+ patients who received chemotherapy in 1L; Patients may receive up to 7 lines of treatment, but 4L+ patients are not included; Ipatasertib in collaboration with Array BioPharma

  6. Tecentriq, ipatasertib: Triple Negative Breast Cancer (TNBC) 2018 estimates for number of patients 6 Source: Roche/Genentech; Ipatasertib in collaboration with Array BioPharma

  7. Avastin: Ovarian Cancer (OC) 2018 estimates for number of patients 7 Source: Roche/Genentech

  8. Tecentriq, Avastin: Non Squamous Non Small Cell Lung Cancer (NSq NSCLC) 2018 estimates for number of patients 8 Source: Roche/Genentech

  9. Alecensa: ALK+ metastatic Non Small Cell Lung Cancer (mNSCLC) 2018 estimates for number of patients 9 Source: Roche/Genentech; Alecensa in collaboration with Chugai

  10. Tecentriq: Small Cell Lung Cancer (SCLC) 2018 estimates for number of patients 10 Source: Roche/Genentech

  11. Zelboraf: Adjuvant BRAF+ stage IIc and III Melanoma 2018 estimates for number of patients 11 Source: Roche/Genentech; Zelboraf in collaboration with Plexxikon, a member of Daiichi Sankyo Group

  12. Zelboraf: 1L BRAF+ metastatic Melanoma (mM) 2018 estimates for number of patients 12 Source: Roche/Genentech; Zelboraf in collaboration with Plexxikon, a member of Daiichi Sankyo Group

  13. Erivedge: Advanced Basal Cell Carcinoma (BCC) 2018 estimates for number of patients 13 Source: Roche/Genentech

  14. Avastin: Colorectal Cancer (CRC) • The target population for Avastin in 1L CRC is ~124,000 patients and in 2L CRC ~78,600 patients 2018 estimates for number of patients 14 Source: Roche/Genentech

  15. Tecentriq: Adjuvant Muscle Invasive Bladder Cancer (MIBC) 2018 estimates for number of patients 15 Source: Roche/Genentech

  16. Tecentriq: Metastatic Urothelial Bladder Cancer (mUBC) 2018 estimates for number of patients 16 Source: Roche/Genentech

  17. Tecentriq: Renal Cell Carcinoma (RCC) 2018 estimates for number of patients 17 Source: Roche/Genentech

  18. Gazyva, Rituxan: Indolent Non-Hodgkin`s Lymphoma (iNHL) 2018 estimates for number of patients 18 Source: Roche/Genentech; Gazyva in collaboration with Biogen

  19. Polatuzumab vedotin, Rituxan: Aggressive Non-Hodgkin`s Lymphoma (aNHL/DLBCL) 2018 estimates for number of patients 19 Source: Roche/Genentech; Polatuzumab vedotin in collaboration with Seattle Genetics; DLBCL=diffuse large B-Cell Non- Hodgkin’s lymphoma;

  20. Gazyva, Venclexta, Rituxan: Chronic Lymphocytic Leukemia (CLL) 2018 estimates for number of patients 20 Source: Roche/Genentech; Gazyva in collaboration with Biogen; Venclexta in collaboration with AbbVie

  21. Venclexta, idasanutlin: Acute Myeloid Leukemia (AML) 2018 estimates for number of patients 21 Source: Roche/Genentech; Venclexta in collaboration with AbbVie

  22. Venclexta: Multiple Myeloma (MM) 2018 estimates for number of patients 22 Source: Roche/Genentech; Venclexta in collaboration with AbbVie

  23. Oncology Hemophilia A Ophthalmology Infectious diseasese Neuroscience Immunology 23

  24. Hemlibra: Hemophilia A 2018 estimates for number of patients 24 Source: Roche/Genentech; Hemlibra in collaboration with Chugai

  25. Oncology Hemophilia A Ophthalmology Infectious diseasese Neuroscience Immunology 25

  26. Faricimab, Port Delivery System (PDS), Lucentis: Age-related Macular Degeneration (AMD) 2,1m 2018 estimates for number of patients 2,0m 1,8m 1,8m 1,7m 1,6m 26 Source: Roche/Genentech

  27. Faricimab, Port Delivery System (PDS), Lucentis: Diabetic Macular Edema (DME) 2018 estimates for number of patients 2,4m 2,0m 1,7m 1,3m 1,2m 0,9m 27 Source: Roche/Genentech

  28. Port Delivery System (PDS), Lucentis: Retinal Vein Occlusion (RVO) 2018 estimates for number of patients 28 Source: Roche/Genentech

  29. Oncology Hemophilia A Ophthalmology Infectious diseasese Neuroscience Immunology 29

  30. Baloxavir marboxil: Influenza A & B 2018 estimates for number of patients 30 Source: Roche/Genentech; Baloxavir marboxil co-developed with Shionogi with Roche holding worldwide license excluding Japan and Taiwan

  31. Oncology Hemophilia A Ophthalmology Infectious diseasese Neuroscience Immunology 31

  32. 2018 estimates for number of patients Source: Roche/Genentech Multiple Sclerosis (MS) Ocrevus: 2018 estimates for number of patients 32

  33. Risdiplam (RG7916): Spinal Muscular Atrophy (SMA) 2018 estimates for number of patients 33 Source: Roche/Genentech; Risdiplam in collaboration with PTC Therapeutics and SMA Foundation

  34. Myostatin inhibiting adnectin fusion protein (RG6206): Duchenne Muscular Dystrophy (DMD) 2018 estimates for number of patients 34 Source: Roche/Genentech

  35. HTT-ASO (RG6042): Huntington’s Disease (HD) 2018 estimates for number of patients 35 Source: Roche/Genentech; HTT-ASO licensed from IONIS Pharmaceuticals

  36. Balovaptan (RG7314): Autism Spectrum Disorder (ASD) There are no FDA approved pharmacologic treatments for the core symptoms of ASD so today no one is treated with a pharmacologic for the core symptoms of Autism Spectrum Disorder* 2018 estimates for number of patients 36 Source: Roche/Genentech; *Pharmacologics for associated symptoms of Autism are available

  37. Crenezumab, gantenerumab: Alzheimer’s Disease (AD) 2018 estimates for number of patients 37 Source: Roche/Genentech; aMCI=amnestic mild cognitive impairment; Crenezumab in collaboration with AC Immune; Gantenerumab in collaboration with MorphoSys

  38. Satralizumab (RG6168): Neuromyelitis Optica (NMO) 2018 estimates for number of patients 38 Source: Roche/Genentech; Clinical developpment by Chugai

  39. Prasinezumab (RG7935): Parkinson’s Disease (PD) 2018 estimates for number of patients 39 Source: Roche/Genentech; H&Y: Hoehn & Yahr scale; Prasinezumab in collaboration with Prothena

  40. Oncology Hemophilia A Ophthalmology Infectious diseasese Neuroscience Immunology 40

  41. Esbriet: Idiopathic Pulmonary Fibrosis (IPF) 2018 estimates for number of patients 41 Source: Roche/Genentech

  42. Xolair: Moderate to severe Asthma 2018 estimates for number of patients 42 Source: Roche/Genentech

  43. Actemra , Rituxan: Rheumatoid Arthritis (RA) Global target population for Actemra and Rituxan in rheumatoid US patients treated with biologics by line arthritis is ~1.2M biologics eligible patients. of therapy (thousands) 2018 estimates for number of patients 43 Source: Roche/Genentech; Actemra in collaboration with Chugai

  44. Actemra: Systemic Juvenile Idiopathic Arthritis (sJIA) 2018 estimates for number of patients 44 Source: Roche/Genentech; Actemra in collaboration with Chugai

  45. Actemra: Polyarticular Juvenile Idiopathic Arthritis (pJIA) 2018 estimates for number of patients 45 Source: Roche/Genentech; Actemra in collaboration with Chugai

  46. Actemra: Giant Cell Arteritis (GCA) 2018 estimates for number of patients 46 Source: Roche/Genentech; Actemra in collaboration with Chugai

  47. Etrolizumab: Ulcerative Colitis (UC) 2018 estimates for number of patients 47 Source: Roche/Genentech

  48. Etrolizumab: Crohn’s Disease (CD) 2018 estimates for number of patients 48 Source: Roche/Genentech

  49. Doing now what patients need next

Recommend

ETA Appendix F Presentation April 17, 2019 Appendix F - Percent Increase applied to Appendix

ETA Appendix F Presentation April 17, 2019 Appendix F - Percent Increase applied to Appendix

ETA Appendix F Presentation April 17, 2019 Appendix F - Percent Increase applied to Appendix F at all levels - Sports and activities added - Areas updated and/or changed - Appendix F Fund at Each level - Appendix F Handbook will be

439 views • 17 slides
Appendix F Appendix F CERN Probably one of the most incredible experiments in the world!

Appendix F Appendix F CERN Probably one of the most incredible experiments in the world!

Appendix F Appendix F CERN Probably one of the most incredible experiments in the world! Training & recruitment opportunities Appendix F Appendix F An Aerial View of CERN Appendix F 1. Accelerators: Powerful machines capable of

332 views • 30 slides
A4 APPENDIX Appendix 4 R APPENDIX 4 Board of Directors Report Presentation of the agenda for

A4 APPENDIX Appendix 4 R APPENDIX 4 Board of Directors Report Presentation of the agenda for

A4 APPENDIX Appendix 4 R APPENDIX 4 Board of Directors Report Presentation of the agenda for the combined Ordinary and Extraordinary General Meeting of May 27, 2014 This document outlines the key issues in the draft resolutions Appropriation

556 views • 13 slides
APPENDIX 4 Presentation of the agenda for the Combined Shareholders Meeting of May 27, 2020

APPENDIX 4 Presentation of the agenda for the Combined Shareholders Meeting of May 27, 2020

.................................... .................................... .................................... ........... .. ........... .. ............. ............. ............. APPENDIX ............. ............. APPENDIX 4

325 views • 31 slides
APPENDICES appendix 1. Systems maps appendix 1. Systems maps appendix 1. Systems maps appendix

APPENDICES appendix 1. Systems maps appendix 1. Systems maps appendix 1. Systems maps appendix

APPENDICES appendix 1. Systems maps appendix 1. Systems maps appendix 1. Systems maps appendix 1. Systems maps appendix 2. Affinity diagram Insights (next few slides)

322 views • 30 slides
SI232 Slide Set #6: Digital Logic (Appendix B) 1 2 Appendix Goals Logic Design Digital

SI232 Slide Set #6: Digital Logic (Appendix B) 1 2 Appendix Goals Logic Design Digital

ADMIN Very different material! Reading Appendix: Read B.1, B.2, B.3. Skim B.5. SI232 Slide Set #6: Digital Logic (Appendix B) 1 2 Appendix Goals Logic Design Digital Signals Establish an understanding of the basics of

368 views • 4 slides
IC220 Slide Set #6: Digital Logic (Appendix B) 1 2 Appendix Goals Logic Design Digital

IC220 Slide Set #6: Digital Logic (Appendix B) 1 2 Appendix Goals Logic Design Digital

ADMIN Very different material! Reading Appendix: Read B.1, B.2, B.3. Skim B.5. IC220 Slide Set #6: Digital Logic (Appendix B) 1 2 Appendix Goals Logic Design Digital Signals Establish an understanding of the basics of

294 views • 3 slides
Environmental Quality Council Proposed Chapter 1, Appendix H Rule Proposed Chapter 1, Appendix H

Environmental Quality Council Proposed Chapter 1, Appendix H Rule Proposed Chapter 1, Appendix H

Environmental Quality Council Proposed Chapter 1, Appendix H Rule Proposed Chapter 1, Appendix H Rule Kevin Harvey Testimony to the EQC on October 28, 2008 Overview My Background Soil and Water Chemistry Overview Comments on Appendix

890 views • 42 slides
Introduction to Risk Parity and Budgeting Appendix A Technical Appendix Thierry Roncalli

Introduction to Risk Parity and Budgeting Appendix A Technical Appendix Thierry Roncalli

Introduction to Risk Parity and Budgeting Appendix A Technical Appendix Thierry Roncalli & CRC Press c Evry University & Lyxor Asset Management, France Instructors may find the description of the book at the following

439 views • 13 slides
Appendix C Public Involvement and Agency Coordination C2 - PUBLIC INVOLVEMENT MEETINGS PART 3

Appendix C Public Involvement and Agency Coordination C2 - PUBLIC INVOLVEMENT MEETINGS PART 3

Appendix C Public Involvement and Agency Coordination C2 - PUBLIC INVOLVEMENT MEETINGS PART 3 OCTOBER 27, 2011 Meeting Appendices APPENDICES Appendix A Promotional Materials Appendix B Scripted PowerPoint APPENDIX A 4 ON THE

670 views • 63 slides
Readings Covered Further Readings Ware: Evaluation Appendix Ware, Appendix C: The Perceptual

Readings Covered Further Readings Ware: Evaluation Appendix Ware, Appendix C: The Perceptual

Readings Covered Further Readings Ware: Evaluation Appendix Ware, Appendix C: The Perceptual Evaluation of Visualization Techniques and Task-Centered User Interface Design, Clayton Lewis and John Rieman, perceptual evaluation of infovis

315 views • 4 slides
APPENDIX Appendix Presentation Slides MICHIGAN TECHNOLOGICAL UNIVERSITY H-STEM INTRODUCTIONS

APPENDIX Appendix Presentation Slides MICHIGAN TECHNOLOGICAL UNIVERSITY H-STEM INTRODUCTIONS

APPENDIX Appendix Presentation Slides MICHIGAN TECHNOLOGICAL UNIVERSITY H-STEM INTRODUCTIONS CASE STUDIES & TRENDS VISIONING 1.INTRODUCTIONS H-STEM Engineering & Health Technologies Complex | Visioning Workshop Report 31 PROJECT

927 views • 49 slides
The PDL Process Faculty Workshop Spring 2015 Appendix P3 the report Article 17: Professional

The PDL Process Faculty Workshop Spring 2015 Appendix P3 the report Article 17: Professional

Appendix P1: the application Appendix P2 the change request The PDL Process Faculty Workshop Spring 2015 Appendix P3 the report Article 17: Professional Development Leave available online: fa.fhda.edu, http://hr.fhda.edu/_faculty-

401 views • 22 slides
Appendix Figure D2. Map of individualism scores. Source: Hofstede (2001). Appendix Figure D3. Map

Appendix Figure D2. Map of individualism scores. Source: Hofstede (2001). Appendix Figure D3. Map

APPENDIX C Questions from Hofstedes survey used to identify individualism (source Exhibit 5.11 in Hofstede (2001)): 1. Have challenging work to do work from which you can get a personal sense of accomplishment [challenge]. 2. Live in an

309 views • 7 slides
FLOW CHART A FOLLOW-UP ON POSITIVE TEST KIT RESULTS Appendix N Flow Chart Testing to

FLOW CHART A FOLLOW-UP ON POSITIVE TEST KIT RESULTS Appendix N Flow Chart Testing to

APPENDIX N FLOW CHART A FOLLOW-UP ON POSITIVE TEST KIT RESULTS Appendix N Flow Chart Testing to determine a presumptive positive can be performed by an approved industry analyst or by a certified entity. Appendix N Flow Chart

526 views • 18 slides
APPENDIX APPENDIX JAERI DEMO Design Poloidal Ring Coil Cryostat Coil Gap Rib Panel Blanket

APPENDIX APPENDIX JAERI DEMO Design Poloidal Ring Coil Cryostat Coil Gap Rib Panel Blanket

APPENDIX APPENDIX JAERI DEMO Design Poloidal Ring Coil Cryostat Coil Gap Rib Panel Blanket Maint. Plasma Port Vacuum Vessel Toroidal Coil Center Solenoid Coil FNT: Components from Edge of Plasma to TFC. Blanket / Divertor immediately

508 views • 14 slides
13 th January 2020 Ruskington B1188 Rectory Road Proposed Zebra Crossing facility APPENDIX A

13 th January 2020 Ruskington B1188 Rectory Road Proposed Zebra Crossing facility APPENDIX A

Agenda Item 4.2 Planning and Regulation Committee Page 18 13 th January 2020 Ruskington B1188 Rectory Road Proposed Zebra Crossing facility APPENDIX A Page 19 Appendix B Traffic survey counts Page 20 Appendix C Pedestrian survey

250 views • 6 slides
Appendix C: Quality Assurance Process PowerPoint Slides C-2 Appendix C: Quality Assurance Process

Appendix C: Quality Assurance Process PowerPoint Slides C-2 Appendix C: Quality Assurance Process

Appendix C: Quality Assurance Process Slides Description The Quality Assurance for Tuberculosis Surveillance Data: A Guide and Toolkit is accompanied by a PowerPoint slide set for use in presentations and training programs. Images of the

474 views • 18 slides
APPENDIX 3: HISTOLOGY SLIDE CATALOGUE - INDEX OF TISSUES Adipose tissue 4A, 13 Adrenal 29, 30

APPENDIX 3: HISTOLOGY SLIDE CATALOGUE - INDEX OF TISSUES Adipose tissue 4A, 13 Adrenal 29, 30

APPENDIX 3: HISTOLOGY SLIDE CATALOGUE - INDEX OF TISSUES Adipose tissue 4A, 13 Adrenal 29, 30 Aorta 33, 34, 34A Anal canal 73 Appendix 71 Artery 1, 1A, 31, 31A, 33, 34, 34A Bladder, urinary 84, 85 Blood 45, 45A Bone, adult 10,

66 views • 3 slides
SPECIES LISTED UNDER CITES APPENDIX II AFTER CoP 17 Decision for wood species Inclusion of

SPECIES LISTED UNDER CITES APPENDIX II AFTER CoP 17 Decision for wood species Inclusion of

SPECIES LISTED UNDER CITES APPENDIX II AFTER CoP 17 Decision for wood species Inclusion of all Dalbergia spp in Cites Appendix II, except Brazilian Rosewood ( Dalbergia nigra ), which is in Appendix I). Inclusion of three Bubinga species

195 views • 16 slides
Appendix. SMA modeling. A review on phenomenological shape memory alloy constitutive modeling

Appendix. SMA modeling. A review on phenomenological shape memory alloy constitutive modeling

Appendix. SMA modeling. A review on phenomenological shape memory alloy constitutive modeling approaches The present appendix is organized in three parts. Part 1 considers various modeling methodologies, focusing on continuum thermodynamics with

443 views • 16 slides
APPENDIX G Visioning Goal # 2 Presentation Buellton Bicycle and Pedestrian Master Plan

APPENDIX G Visioning Goal # 2 Presentation Buellton Bicycle and Pedestrian Master Plan

APPENDIX G Visioning Goal # 2 Presentation Buellton Bicycle and Pedestrian Master Plan Appendix Page G GROUP 2 MEMBERS Fr Fred L Luna Peggy Brier ggy Brierton on Shar Sharyn yne Merritt erritt Joe Serna Joe Serna

484 views • 16 slides
2019-20 Draft Budget Appendix April 17, 2019 30 Appendix contents Accounting policies

2019-20 Draft Budget Appendix April 17, 2019 30 Appendix contents Accounting policies

2019-20 Draft Budget Appendix April 17, 2019 30 Appendix contents Accounting policies Financial principles Budget process flowchart SMA enrolment corridor FTE enrolment summary Budget operating summary Operating

1.1k views • 31 slides
ANOTHER APPENDIX TO New Performance Metrics based on Multigrade Relevance: Their Application to

ANOTHER APPENDIX TO New Performance Metrics based on Multigrade Relevance: Their Application to

ANOTHER APPENDIX TO New Performance Metrics based on Multigrade Relevance: Their Application to Question Answering Tetsuya Sakai Knowledge Media Laboratory, Toshiba Corporate R&D Center tetsuya.sakai@toshiba.co.jp This appendix shows the

340 views • 8 slides

More recommend